Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989009 | 0.90 | KDM4E (0.40) | KDM4EHSD17B10CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23046207 | 0.81 | ALDH1A1 (0.39) | KDM4EHSD17B10CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL447421 | 0.81 | ALDH1A1 (0.39) | KDM4EHSD17B10CYP1A2CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL31561894 | 0.79 | ALDH1A1 (0.38) | KDM4EHSD17B10CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15606427 | 0.78 | MAPK1 (0.37) | MAPK1GAA | |
| SCHEMBL14882598 | 0.78 | MAPK1 (0.37) | MAPK1GAA | |
| SCHEMBL6506166 | 0.77 | KDM4E (0.45) | KDM4EHSD17B10CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10963921 | 0.76 | — | — | |
| SCHEMBL17231979 | 0.76 | — | — | |
| SCHEMBL23479282 | 0.76 | PRCP (0.36) | KDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| CN-101128202-A | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORP (US) | 2008-02-20 | — | — | CN | disclosed |
| EP-1833481-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION | 2006-09-21 | — | — | US | disclosed |
| WO-2006065794-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-0154142-B1 | SUBSTITUTED HEXAHYDRO ARYLQUINOLIZINES | MERCK & CO. INC. (US) | 1989-07-12 | — | — | EP | disclosed |
| US-4690928-A | ANTIDEPRESSANTS, HYPOTENSIVE AGENTS, ANTIDIABETIC, ANTIOBESITY AND ANTICOAGULANT | MERCK & CO., INC. (US) | 1987-09-01 | — | — | US | disclosed |
| US-4673680-A | 1,3,4,6,7,12B-HEXAHYDRO-2H-BENZO(B)(FURO OR THIENO)(2,3-A) QUINOLIZIN-2-YL-AMINE DERIVATIVES | MERCK & CO., INC., A CORP. OF NJ | 1987-06-16 | — | — | US | disclosed |
| EP-0216247-A2 | Use of alpha 2 adrenergic receptor antagonists for the production of pharmaceutical compositions for treating colonic spasm, irritable bowel syndrome and constipation and process for preparing such pharmaceutical compositions | MERCK & CO. INC. (US) | 1987-04-01 | — | — | EP | disclosed |
| EP-0154142-A1 | Substituted hexahydro arylquinolizines | MERCK & CO. INC. (US) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | FNTB, FNTA, FDPS | KDM4E 3826/4885HSD17B10 332/4885CYP1A2 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.